GlassScriptPhysician profile
Krystle Gish
NPI 1669096335
$5,273.49
in general payments reported to CMS, 2019-2025
40 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $111 · 2023: $479 · 2024: $1,542 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,741.10 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.52 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $494.49 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $479.99 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $443.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $361.50 | 2021-2025 | Spravato |
| Pfizer INC. | $350.54 | 2023-2025 | |
| Amgen INC. | $238.45 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $233.94 | 2025 | |
| Glaxosmithkline, LLC. | $204.39 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Eisai INC. | $157.35 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.95 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $144.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.28 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $114.16 | 2023-2025 | Rexulti |
| Grifols USA, LLC | $103.08 | 2023 | Xembify |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $100.27 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $91.01 | 2023-2025 | Ajovy |
| Sumitomo Pharma America, INC. | $90.02 | 2025 | Gemtesa |
| Sandoz INC. | $74.29 | 2024-2025 | Hyrimoz |
| Idorsia Pharmaceuticals US INC | $62.23 | 2023-2024 | Quviviq |
| Dexcom, INC. | $55.03 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $53.27 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $48.77 | 2023-2025 | Watchman Flx, Watchman Access System |
| Currax Pharmaceuticals LLC | $41.62 | 2023-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.59 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.00 | 2024 | Xifaxan |
| Globus Medical, INC. | $32.91 | 2025 | Senza |
| Stryker Corporation | $31.99 | 2025 | Clottriever Bold Catheter |
| Kowa Pharmaceuticals America, INC. | $30.78 | 2024-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $26.88 | 2024-2025 | Voquezna |
| Ge Healthcare | $26.53 | 2025 | |
| Corium, LLC | $26.15 | 2024 | Azstarys |
| Mylan Specialty L.P. | $23.58 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.38 | 2025 | Recorlev |
| Alnylam Pharmaceuticals INC. | $21.57 | 2025 | Givlaari |
| Viiv Healthcare Company | $20.41 | 2024 | Apretude |
| Tonix Medicines, INC. | $18.94 | 2025 | Tonmya |
| Axsome Therapeutics, INC. | $17.06 | 2025 | Auvelity |
| Acella Pharmaceuticals, LLC | $15.78 | 2025 | NP Thyroid 60 |
| Evofem Biosciences, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystle Gish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.